Article Text

Download PDFPDF
Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease
  1. James A Eaden1,
  2. Alexander Charles Ford1,2
  1. 1Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK
  2. 2Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
  1. Correspondence to Dr Alexander Charles Ford, Leeds Gastroenterology Institute, Room 125, 4th Floor, Bexley Wing, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK; alexf12399{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read the article by Sands et al1 with interest. The efficacy of granulocyte/monocyte apheresis (GMA) in inflammatory bowel disease (IBD) is controversial, with previous studies mainly conducted in Japan, involving small numbers of patients, often without sham controls.2–4 The authors should, therefore, be congratulated for performing a large, randomised, double-blind, sham-controlled study of GMA in moderate to severely active Crohn's disease in a Western population.

The …

View Full Text


  • Contributors JEA and ACF drafted the manuscript.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.